• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
"Tell Juliana": acceptability of the candidate microbicide VivaGel® and two placebo gels among ethnically diverse, sexually active young women participating in a phase 1 microbicide study.“告诉朱莉安娜”:在参与 1 期杀微生物剂研究的不同种族、活跃的年轻女性中,候选杀微生物剂 VivaGel®和两种安慰剂凝胶的可接受性。
AIDS Behav. 2012 Oct;16(7):1761-74. doi: 10.1007/s10461-011-0028-6.
2
Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004).MTN-004 研究:评价 SPL7013 凝胶(VivaGel)阴道用药在性活跃年轻女性中的阴道安全性和可接受性的 1 期随机临床试验。
AIDS. 2011 May 15;25(8):1057-64. doi: 10.1097/QAD.0b013e328346bd3e.
3
Young women's experience with using videoconferencing for the assessment of sexual behavior and microbicide use.年轻女性使用视频会议进行性行为和杀微生物剂使用评估的经历。
Telemed J E Health. 2013 Nov;19(11):866-71. doi: 10.1089/tmj.2013.0008. Epub 2013 Sep 19.
4
Variations in microbicide gel acceptability among young women in the USA and Puerto Rico.美国和波多黎各年轻女性对杀微生物剂凝胶接受度的差异。
Cult Health Sex. 2012;14(2):151-66. doi: 10.1080/13691058.2011.630099. Epub 2011 Nov 15.
5
A phase I randomized placebo controlled trial of the safety of 3% SPL7013 Gel (VivaGel®) in healthy young women administered twice daily for 14 days.一项 I 期随机安慰剂对照试验,评估 3% SPL7013 凝胶(VivaGel®)在健康年轻女性中的安全性,每日两次给药,共 14 天。
PLoS One. 2011 Jan 20;6(1):e16258. doi: 10.1371/journal.pone.0016258.
6
User-identified gel characteristics: a qualitative exploration of perceived product efficacy of topical vaginal microbicides.用户识别的凝胶特性:局部阴道杀菌剂感知产品功效的定性探索。
Arch Sex Behav. 2014 Oct;43(7):1459-67. doi: 10.1007/s10508-013-0235-5. Epub 2014 Jan 23.
7
Appropriateness of hydroxyethylcellulose gel as a placebo control in vaginal microbicide trials: a comparison of the two control arms of HPTN 035.羟乙基纤维素凝胶作为阴道杀微生物剂试验安慰剂对照的适宜性:HPTN 035 研究的两个对照组比较。
J Acquir Immune Defic Syndr. 2013 May 1;63(1):120-5. doi: 10.1097/QAI.0b013e31828607c5.
8
Covert use, vaginal lubrication, and sexual pleasure: a qualitative study of urban U.S. Women in a vaginal microbicide clinical trial.隐性使用、阴道润滑和性快感:美国城市女性阴道杀微生物剂临床试验的定性研究。
Arch Sex Behav. 2010 Jun;39(3):748-60. doi: 10.1007/s10508-009-9509-3. Epub 2009 Jul 28.
9
Prevention, Partners, and Power Imbalances: Women's Views on How Male Partners Affected Their Adherence to Vaginal Microbicide Gels During HIV Prevention Trials in Africa.预防、伴侣和权力失衡:女性对男性伴侣如何影响其在非洲艾滋病毒预防试验中坚持使用阴道杀微生物凝胶的看法。
J Acquir Immune Defic Syndr. 2020 Dec 1;85(4):458-465. doi: 10.1097/QAI.0000000000002463.
10
Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study.替诺福韦凝胶作为阴道杀菌剂在I期试验女性中的可接受性:一项混合方法研究。
J Womens Health (Larchmt). 2008 Apr;17(3):383-92. doi: 10.1089/jwh.2006.0325.

引用本文的文献

1
Dendrimer-Mediated Delivery of DNA and RNA Vaccines.树枝状聚合物介导的DNA和RNA疫苗递送
Pharmaceutics. 2023 Mar 30;15(4):1106. doi: 10.3390/pharmaceutics15041106.
2
Dendrimers, an Emerging Opportunity in Personalized Medicine?树枝状大分子,个性化医疗的新机遇?
J Pers Med. 2022 Aug 19;12(8):1334. doi: 10.3390/jpm12081334.
3
Acceptability of an extended duration vaginal ring for HIV prevention and interest in a multi-purpose ring.接受度研究:延长使用时长的阴道环预防 HIV 的效果,以及对多功能阴道环的兴趣。
PLoS One. 2022 Feb 22;17(2):e0263664. doi: 10.1371/journal.pone.0263664. eCollection 2022.
4
Baseline and time-updated factors in preclinical development of anionic dendrimers as successful anti-HIV-1 vaginal microbicides.作为成功的抗 HIV-1 阴道杀微生物剂,在阴离子树状聚合物的临床前开发中,基线和时间更新因素。
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2022 May;14(3):e1774. doi: 10.1002/wnan.1774. Epub 2022 Jan 12.
5
The Role of Volume in the Perceptibility of Topical Vaginal Formulations: User Sensory Perceptions and Experiences of Heterosexual Couples During Vaginal Sex.体积在局部阴道制剂可感知性中的作用:异性恋夫妇在阴道性行为期间的用户感官感知和体验。
AIDS Res Hum Retroviruses. 2020 Dec;36(12):1059-1070. doi: 10.1089/AID.2020.0138. Epub 2020 Nov 3.
6
A Mixed-Methods Study Examining Adherence to and Acceptability of Intravaginal Rings for HIV Prevention: Behavioral Results of MTN-027.一项关于阴道环预防HIV依从性和可接受性的混合方法研究:MTN - 027的行为学结果
AIDS Behav. 2020 Feb;24(2):607-616. doi: 10.1007/s10461-019-02457-0.
7
Qualitative exploration of intrinsic and extrinsic factors that influence acceptability of semisoft vaginal suppositories.对影响半软质阴道栓剂可接受性的内在和外在因素的定性探索。
BMC Womens Health. 2018 Oct 20;18(1):170. doi: 10.1186/s12905-018-0657-2.
8
Effects of gel volume on pharmacokinetics for vaginal and rectal applications of combination DuoGel-IQB4012, a dual chamber-dual drug HIV microbicide gel, in pigtailed macaques.凝胶体积对 DuoGel-IQB4012(一种双室双药 HIV 杀微生物剂凝胶)阴道和直肠应用于长尾猕猴的药代动力学的影响。
Drug Deliv Transl Res. 2018 Oct;8(5):1180-1190. doi: 10.1007/s13346-018-0538-0.
9
Evaluation of immunological markers of ovine vaginal irritation: Implications for preclinical assessment of non-vaccine HIV preventive agents.评价绵羊阴道刺激的免疫标志物:对非疫苗 HIV 预防制剂临床前评估的意义。
J Reprod Immunol. 2017 Nov;124:38-43. doi: 10.1016/j.jri.2017.09.014. Epub 2017 Oct 13.
10
Acceptability of and Adherence to an Antiretroviral-Based Vaginal Microbicide among Pregnant Women in the United States.美国孕妇对基于抗逆转录病毒的阴道杀微生物剂的可接受性和依从性。
AIDS Behav. 2018 Feb;22(2):402-411. doi: 10.1007/s10461-017-1811-9.

本文引用的文献

1
Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004).MTN-004 研究:评价 SPL7013 凝胶(VivaGel)阴道用药在性活跃年轻女性中的阴道安全性和可接受性的 1 期随机临床试验。
AIDS. 2011 May 15;25(8):1057-64. doi: 10.1097/QAD.0b013e328346bd3e.
2
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.替诺福韦凝胶作为一种抗逆转录病毒的杀微生物剂,用于预防女性感染艾滋病毒的有效性和安全性。
Science. 2010 Sep 3;329(5996):1168-74. doi: 10.1126/science.1193748. Epub 2010 Jul 19.
3
Unprotected anal intercourse and sexually transmitted diseases in high-risk heterosexual women.无保护肛交与高危异性性行为妇女中的性传播疾病。
Am J Public Health. 2011 Apr;101(4):745-50. doi: 10.2105/AJPH.2009.181883. Epub 2010 Jun 17.
4
Efficacy dilution in randomized placebo-controlled vaginal microbicide trials.随机安慰剂对照阴道微生物杀灭剂试验中的疗效稀释
Emerg Themes Epidemiol. 2009 Oct 9;6:5. doi: 10.1186/1742-7622-6-5.
5
Women's experiences with anal sex: motivations and implications for STD prevention.女性肛交经历:动机及对性传播疾病预防的影响
Perspect Sex Reprod Health. 2009 Sep;41(3):142-9. doi: 10.1363/4114209.
6
Microbicide acceptability research: recent findings and evolution across phases of product development.杀微生物剂可接受性研究:产品开发各阶段的最新发现与进展
Curr Opin HIV AIDS. 2008 Sep;3(5):581-6. doi: 10.1097/COH.0b013e32830aba00.
7
Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study.替诺福韦凝胶作为阴道杀菌剂在I期试验女性中的可接受性:一项混合方法研究。
J Womens Health (Larchmt). 2008 Apr;17(3):383-92. doi: 10.1089/jwh.2006.0325.
8
Assessing microbicide acceptability: a comprehensive and integrated approach.评估杀微生物剂的可接受性:一种全面综合的方法。
AIDS Behav. 2008 Mar;12(2):272-83. doi: 10.1007/s10461-007-9266-z. Epub 2007 Jun 26.
9
Acceptability of PRO2000 vaginal gel among HIV un-infected women in Pune, India.印度浦那未感染艾滋病毒女性对PRO2000阴道凝胶的接受度。
AIDS Care. 2007 Jul;19(6):817-21. doi: 10.1080/09540120601133576.
10
Acceptability of Carraguard vaginal gel use among Thai couples.泰国夫妇对使用角叉菜胶阴道凝胶的接受度。
AIDS. 2006 Nov 14;20(17):2141-8. doi: 10.1097/QAD.0b013e32801086c9.

“告诉朱莉安娜”:在参与 1 期杀微生物剂研究的不同种族、活跃的年轻女性中,候选杀微生物剂 VivaGel®和两种安慰剂凝胶的可接受性。

"Tell Juliana": acceptability of the candidate microbicide VivaGel® and two placebo gels among ethnically diverse, sexually active young women participating in a phase 1 microbicide study.

机构信息

HIV Center for Clinical and Behavioral Studies, New York State Psychiatric Institute and Columbia University, 1051 Riverside Drive, New York, NY 10032, USA.

出版信息

AIDS Behav. 2012 Oct;16(7):1761-74. doi: 10.1007/s10461-011-0028-6.

DOI:10.1007/s10461-011-0028-6
PMID:21863338
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3272128/
Abstract

This study assessed acceptability of the candidate microbicide VivaGel(®) and two placebo gels among 61 sexually active young US and Puerto Rican women at three sites. Participants were randomly assigned to use one of the gels twice per day for 14 days. At trial completion, 59% of the women in the VivaGel(®) group reported being likely to use the gel in the future, whereas 23% were unlikely to use it and 18% were undecided. Participants reported problems with all three gels, including the "universal" placebo containing hydroxyethyl cellulose (HEC). The most frequent complaints were leakage, interference with sexual behavior, and decreased sexual satisfaction. Some of the complaints are not new but remain unresolved. Women's perceived risk of HIV infection may determine whether the gels are used. Users also may want a choice of viscosity. Poor acceptability of vaginal microbicide formulations may result in poor adherence to gel use during efficacy trials and compromise validity of results.

摘要

本研究评估了候选杀微生物剂 VivaGel(®)和两种安慰剂凝胶在三个地点的 61 名活跃的美国和波多黎各年轻女性中的可接受性。参与者被随机分配每天使用其中一种凝胶两次,持续 14 天。在试验结束时,VivaGel(®)组中有 59%的女性表示将来可能会使用该凝胶,而 23%的女性表示不太可能使用,18%的女性表示不确定。参与者报告了所有三种凝胶的问题,包括含有羟乙基纤维素 (HEC)的“通用”安慰剂。最常见的抱怨是泄漏、性行为干扰和性满意度下降。其中一些抱怨并不是新的,但仍未得到解决。女性对 HIV 感染的感知风险可能决定她们是否使用这些凝胶。使用者可能还希望选择不同的黏度。阴道杀微生物剂配方的可接受性差可能导致在疗效试验中对凝胶使用的依从性差,并影响结果的有效性。